COVID-19 Infection in Fingolimod- or Siponimod-Treated Patients: Case Series

BACKGROUND AND OBJECTIVES: A descriptive analysis of COVID-19 infection in patients with multiple sclerosis (MS) receiving fingolimod or siponimod. METHODS: We reviewed the cases of COVID-19 from postmarketing or ongoing clinical trials reported to Novartis through December 27, 2020. RESULTS: As of...

Descripción completa

Detalles Bibliográficos
Autores principales: Sullivan, Roseanne, Kilaru, Ajay, Hemmer, Bernhard, Campbell Cree, Bruce Anthony, Greenberg, Benjamin M., Kundu, Uma, Hach, Thomas, DeLasHeras, Virginia, Ward, Brian J., Berger, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860466/
https://www.ncbi.nlm.nih.gov/pubmed/34848501
http://dx.doi.org/10.1212/NXI.0000000000001092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860466/
https://www.ncbi.nlm.nih.gov/pubmed/34848501
http://dx.doi.org/10.1212/NXI.0000000000001092

Ejemplares similares